Promising schizophrenia drug faces tough competition
European Pharmaceutical Review
NOVEMBER 25, 2022
LY03010 was well tolerated and showed no unexpected treatment-emergent adverse events (TEAEs) compared to Invega Sustenna ®. Should LY03010 receive US Food and Drug Administration (FDA) approval, Luye Pharma will need to provide solid marketing and competitive pricing to set it apart from competitors and convince payers to reimburse it.”.
Let's personalize your content